June 29, 2018
GREENWICH, CT and CHARLEROI, BELGIUM — Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in MaSTherCell Global. Founded in 2011 (acquired by Orgenesis (NASDAQ: ORGS) in 2015) and based in Charleroi, Belgium, MaSTherCell leverages its world-class facilities, regulatory track record and technical expertise to maintain a leading position as a global manufacturer of cell and gene therapies. The growth equity investment by Great Point will allow MaSTherCell to pursue additional avenues of growth and capitalize on the rapidly expanding market of cell and gene therapies.
MaSTherCell (Manufacturing Synergies for Therapeutic Cells) offers clients process development and contract manufacturing services and is dedicated to all aspects of the cell therapy development and manufacturing process. From technology transfer to end logistics, the Company provides a wide range of services to help biotechnology companies develop and produce their novel drugs. MaSTherCell has facilities in Belgium, South Korea, Israel, and following the GPP investment, will build an additional facility in the United States.
“We are excited to make this investment in MaSTherCell,” Noah Rhodes, Managing Director at Great Point Partners, stated. “We have been pursuing a platform in the cell and gene therapy manufacturing market for some time and believe that MaSTherCell is well-positioned to take advantage of the tailwinds in the market.”
“Great Point’s long track record of investing in the pharmaceutical services industry made them an ideal partner to help accelerate MaSTherCell’s growth and achieve our vision for the company. We look forward to working together to pursue our common goals for expansion,” added Vered Caplan, Chairman of MaSTherCell.
About Great Point Partners
Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.
MaSTherCell is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. At the heart of MaSTherCell is a team of more than 90 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. For more information, visit www.masthercell.com.